GENOMMA LAB INTERNACIONAL ANNOUNCES ITS THIRD QUARTER 2015 RESULTS

Mexico City, Mexico, October 28th, 2015

Genomma Lab Internacional, S.A.B. de C.V. (BMV: LAB.B) ("Genomma Lab" or "the Company"), announced today its results for the quarter ended September 30, 2015. All figures included herein are stated in nominal Mexican pesos and were prepared in accordance with International Financial Reporting Standards (IFRS).

3Q 2015 Highlights (vs. 3Q 2014)

- Net Sales for the third quarter were Ps. 2.62 billion, a decrease of 21.9% compared to the same quarter of 2014; and Ps. 8.37 billion for the nine month period, a decrease of 3.8% compared to 2014.
  - Sales in Mexico were Ps. 822.8 million for the quarter, a decline of 59.2% compared to 2014. For the nine month period, sales in Mexico were Ps. 2.99 billion, down 36.2%, and were in line with our destocking plan.
  - Sales in the U.S.A. operations were Ps. 301.6 million for the quarter, an increase of 146.7% compared to 2014.
  - Sales in the Latin American[(1)] operations were Ps. 1.50 billion for the quarter, an increase of 22.7% compared to 2014.
- In Mexico, sell-out of our products rose 11.9% during the quarter, compared to the same period of 2014. In a year-to-date basis, the sell-out has increased 6.3% (*Company sell-out data: 7.0% growth for OTC products and 5.0% growth for personal care products*) compared to 2014.
- Adjusted EBITDA fell 52.2% in the third quarter to Ps. 406.6 million, representing a 15.5% margin, compared to 25.3% in the same period of 2014.
- Consolidated Net Income amounted to Ps. 188.4 million, representing a margin of 7.2%. Earnings per share amounted to Ps. 1.15, compared to Ps. 1.69 in the same quarter of 2014.
- Free Cash Flow generated year-to-date as of the third quarter amounted to Ps. 550.8 million (excluding movements from the sale of Grupo Marzam), representing a ratio of 6.6% to Net Sales.
- During the third quarter, the Company closed the sale of 50% plus one share of Grupo Marzam and received the first payment for Ps. 1.05 billion; the remaining Ps. 300 million will be collected in the first anniversary of this transaction. As of the end of the third quarter of 2015, Grupo Marzam is only included in Genomma Lab's financial statements as a non-controlling subsidiary.

(1) Latin America includes: Argentina, Bolivia, Brazil, Chile, Colombia, Costa Rica, Dominican Republic, Ecuador, El Salvador, Guatemala, Honduras, Nicaragua, Panama, Paraguay, Peru, Puerto Rico, Trinidad and Tobago, and Uruguay.

Comments from the CEO

Mr. Máximo Juda, Chief Executive Officer, said: "Results for this third quarter were in line with the guidance recently announced during our Investor Day on September 29, including a destocking process in our Mexican operations, which has resulted in a 59.2% decline in sales during the quarter, while achieving stronger results in Latam and the U.S.A.

Our international operations continue to post strong growth rates, 33.9% for the quarter and 34.1% on a year-to-date basis, compared to the same periods of 2014. The U.S.A., Peru, Colombia and Argentina posted the strongest results, recording growth rates above 50% in the quarter. Margins for the quarter were also strong and in line with our expectations; the Latam's EBITDA margin was 27.2% and the U.S.A. EBITDA margin was 26.3%. One of the management's top priorities is to continue delivering strong international results and to continue improving profitability in these operations.

The turnaround process in our Mexican operations, together with the destocking of inventories in the channel, is evolving according to our expectations. The sell-out of our products is being strengthened by the new marketing and commercial strategies, which are focused on a better exhibition and execution at the point of sale. These are having positive results, as seen in the 11.9% sell-out growth in Mexico during the quarter and 6.3% growth on a year-to-date basis, compared to the same periods of 2014.

During the third quarter, the Company reduced its net debt to Ps. 3.98 billion, from Ps. 5.36 billion in the second quarter of this year. In terms of free cash flow, a key focus of the new management team, the Company generated Ps. 550.8 million on a year-to-date basis, which excludes movements derived from Marzam's sale. We will continue strengthening our cash position, while reducing net debt and repurchasing stock in the coming quarters.

We are convinced we are taking the right actions to build a more sustainable Company. We face challenges in the next quarters, but we are certain that our disclosure efforts will better reflect our strategy as we focus on increasing the long term value for our stakeholders."

Consolidated Results of Operations for the Third Quarter of 2015

The following table shows consolidated results of operations, in millions of pesos (except share and per-share data), and margins are shown as a percentage of Net Sales. All figures for 2015 are compared to the same period of the previous year:

For the third quarter and nine month period ended September 30, 2015 and 2014
(In millions pesos)

	3rd Quarter			January - September		
	2015	2014	%Var	2015	2014	%Var
Net Sales	2,624.2	3,359.5	(21.9)	8,367.5	8,697.7	(3.8)
Gross Profit	1,797.7	2,314.5	(22.3)	5,837.1	6,023.4	(3.1)
Gross Margin	68.5%	68.9%	(0.4)	69.8%	69.3%	0.5
Adjusted EBITDA[1]	406.6	850.0	(52.2)	1,458.3	1,839.9	(20.7)
Adjusted EBITDA Margin	15.5%	25.3%	(9.8)	17.4%	21.2%	(3.8)
Operating Income	359.5	823.8	(56.4)	1,338.7	1,770.7	(24.4)
Operating Income Margin	13.7%	24.5%	(10.8)	16.0%	20.4%	(4.4)
Net Income of Majority Shareholders	182.5	472.55	(61.4)	679.3	934.0	(27.3)
Net Income of Majority Shareholders Margin	7.0%	14.1%	(7.1)	8.1%	10.7%	(2.6)
Weighted Average Number of Shares Outstanding	1,032,857,391	1,048,545,892	(1.5)	1,037,272,413	1,048,670,191	(1.1)
EPS (12 months)[2]	1.15	1.69	(32.0)	1.15	1.69	(32.3)

[1] Adjusted EBITDA has been calculated by excluding non-recurring expenses. EBITDA is calculated by adding depreciation and amortization to the Operating Income.

[2] Earnings per share are for the last 12 months and were calculated using the weighted average of shares outstanding for the period. The total number of shares outstanding as of September 30, 2015 is 1,022,539,908.

Net Sales fell 21.9% to Ps. 2.62 billion in the third quarter of 2015, from Ps. 3.36 billion in the third quarter of 2014. The decline in sales is mainly explained by the 59.2% fall in our Mexican business, which is going through a turnaround process, including a reduction in inventories in the channel. The international operations posted a strong 33.9% growth rate, with Latam and the U.S.A. growing 22.7% and 146.7%, respectively, during the quarter.

Segmentation of Sales by Region



(In million pesos)

	3Q15			3Q14			
	Pharma*	**PC**	**Total 3Q15**	**Pharma***	**PC**	**Total 3Q14**	**%Var**
Mexico	425.5	397.3	**822.8**	1,324.2	690.4	**2,014.6**	-59.2%
International	600.8	1,200.7	**1,801.5**	379.0	966.0	**1,344.9**	33.9%
TOTAL	**1,026.3**	**1,597.9**	**2,624.2**	**1,703.2**	**1,656.3**	**3,359.5**	**-21.9%**

	3Q15 YTD			3Q14 YTD			
	Pharma*	**PC**	**Total 3Q15 YTD**	**Pharma***	**PC**	**Total 3Q14 YTD**	**%Var**
Mexico	1,515.1	1,473.8	**2,989.0**	2,892.9	1,792.6	**4,685.6**	-36.2%
International	1,902.1	3,476.4	**5,378.5**	1,182.2	2,829.9	**4,012.1**	34.1%
TOTAL	**3,417.2**	**4,950.2**	**8,367.5**	**4,075.1**	**4,622.6**	**8,697.7**	**-3.8%**

* *Pharma* refers to OTC and generic pharmaceutical products in Mexico and OTC pharmaceutical products in the international operations.

Note: There has been a reclassification of some of our products in our Mexican operations, resulting in a variation in the numbers reported during 2014.

Gross Profit decreased 22.3% to Ps. 1.80 billion in the third quarter of 2015, compared to Ps. 2.31 billion during the third quarter of 2014. Gross Margin decreased 0.4 percentage points, as a percentage of Net Sales, to 68.5% in the third quarter of 2015, compared to 68.9% in the same period of 2014. This margin decrease was primarily due to the destocking process through which the Company is going in its Mexican operations, as sales in this country were significantly lower than the same quarter of 2014 and the margin was affected by fixed costs that are common to the business but do not have a significant effect on regular sales levels.

Selling, General, Marketing and Administrative Expenses, as a percentage of Net Sales, increased 9.6 percentage points to 54.4% in the third quarter of 2015, compared to 44.8% in the same period of 2014. This increase is mainly related to advertising, marketing and POS expenses related to the sell-out of our products in our Mexican sales, which was significantly higher than the sell-in due to the inventory adjustment in the channel. This trend will continue in the following quarters while inventory adjustment is been made.

In Mexico, on a nominal basis and excluding non-recurring expenses, Selling, General, Marketing and Administrative Expenses declined 30.6% to Ps. 581.7 million in the quarter, compared to Ps. 838.6 million in the third quarter of 2014.



Adjusted EBITDA decreased 52.2% to Ps. 406.6 million in the third quarter of 2015, compared to Ps. 850.0 million in the third quarter of 2014. The Adjusted EBITDA margin decreased 9.8 percentage points, as a percentage of Net Sales, to 15.5% in the third quarter of 2015, from 25.3% in the same period of 2014. The Adjusted EBITDA margin decrease was primarily due to higher Selling, General, Marketing and Administrative Expenses (excluding Depreciation and Amortization), as a percentage of Net Sales, as well as higher cost of goods sold, as a percentage of Net Sales. EBITDA was adjusted by excluding non-recurring expenses.

EBITDA Reconciliation

For the third quarter ended September 30, 2015 and 2014
(In million pesos)

	Third Quarter	
	2015	**2014**
Consolidated net income	188.4	487.2
Discontinued operations (income)	(11.0)	-
Income tax expense	80.7	215.6
Not consolidated subsidiaries' loss (income)	1.6	1.4
Comprehensive financing cost (income)	99.9	119.6
Operating income	**359.5**	**823.8**
Depreciation and amortization	27.8	26.2
EBITDA	**387.3**	**850.0**
EBITDA margin	*14.8%*	*25.3%*
Non-recurring expenses[1]	19.3	-
Adjusted EBITDA	**406.6**	**850.0**
Adjusted EBITDA margin	15.5%	25.3%

[1] The non-recurring expenses are related to the downsizing of our headcount in Mexico (severance payments) incurred during 3Q15.

Operating Income decreased 56.4% to Ps. 359.5 million in the third quarter of 2015, compared to Ps. 823.8 million in the third quarter of 2014. Operating Margin, as a percentage of Net Sales, decreased 10.8 percentage points, reaching 13.7% in the third quarter of 2015, from 24.5% in the same period of 2014.

Comprehensive Financing Result represented a loss of Ps. 99.9 million in the third quarter of 2015, compared to the Ps. 119.6 million loss recorded in the third quarter of 2014. This variation was a result of: i) a Foreign Exchange gain amounting to Ps. 68.6 million during the third quarter of 2015, compared to a Ps. 17.1 million gain during the same period of 2014; the gain in this quarter was a result of the appreciation of the US Dollar exchange rate vs. the Company's operating currencies, which was reflected in the Company's cash position in local currencies; ii) an increase of Ps. 12.7 million in Financial Expenses to Ps. 103.8 million during the third quarter of 2015, compared to Ps. 91.1 million during the same period of 2014; iii) a higher Interest Income amounting to Ps. 7.3 million during the third quarter of 2015, compared to Ps. 2.1 million in the same period of 2014; and, iv) a Ps. 72.0 million loss in the third quarter of 2015 related to the Exchange Rate conversion from our foreign operations, compared to a Ps. 47.8 million loss in the same period of 2014.

Consolidated Net Income decreased 61.3% to Ps. 188.4 million in the third quarter of 2015, representing a margin of 7.2% over Net Sales, compared to Ps. 487.2 million in the third quarter of 2014, which represented a margin of 14.5%.

Free Cash Flow year-to-date as of the third quarter 2015 amounted to Ps. 550.8 billion (excluding movements from the sale of Grupo Marzam), representing a ratio of 6.6% to Consolidated Net Sales.

*FCF is calculated as: EBIT(1-Tax Rate) + Depreciation & Amortization - Change in Net Working Capital - Capital Expenditure.

Mexico

Net Sales decreased 59.2% to Ps. 822.8 million in the third quarter of 2015, from Ps. 2.01 billion in the third quarter of 2014.

Net Sales by brands in Mexico are classified as follows:

1) **Base Brands** represent brands launched at least two years prior to the last fiscal year (2013, 2012, 2011 and earlier);
2) **Prior Year Launches** are brands launched during the prior fiscal year (2014);
3) **New Brands** are brands launched during the current fiscal year (2015); and

The decrease in Net Sales during the third quarter, compared to the same period of 2014, resulted from the combination of the following factors:

i) a 59.6% decrease (Ps. 1.20 billion) in **Base Brands**, amounting to Ps. 812.8 million, including line extensions;
ii) a 193.6% increase (Ps. 6.5 million) in **Prior Year Launches** due to the full year effect, including the recent line extensions of these brands, resulting in sales of Ps. 9.8million; and,
iii) Ps. 0.1 million sales in **New Brands** during the third quarter of 2015.

Note: After closing the transaction to sell 50% plus one share of Grupo Marzam, revenues to this company amounted to Ps. 12.9 million.

Sell-out of our products increased 11.9% during the quarter, compared to the same period of 2014, amounting to Ps. 1.23 billion. Year-to-date, sell-out increased 6.3% compared to 2014.

Adjusted EBITDA decreased 116.4% to a loss of Ps. 81.4 million in the third quarter of 2015, compared to Ps. 495.0 million in the third quarter of 2014. The Adjusted EBITDA margin decreased 34.5 percentage points, as a percentage of Net Sales, to negative 9.9% in the third quarter of 2015, from 24.6% in the same period of 2014.

Reduction of Inventories at the Point of Sale amounted to Ps. 393.8 million, in line with the objective for this quarter.

U.S.A.

Net Sales rose 146.7% to Ps. 301.6 million in the third quarter of 2015, from Ps. 122.3 million in the third quarter of 2014.

EBITDA amounted to Ps. 79.4 million in the third quarter of 2015, compared to a loss of Ps. 28.3 million in the third quarter of 2014. The EBITDA margin increased 49.4 percentage points, as a percentage of Net Sales, to 26.3% in the third quarter of 2015, from negative 23.1% in the same period of 2014.

Latin America

Net Sales rose 22.7% to Ps. 1.50 billion in the third quarter of 2015, from Ps. 1.22 billion in the third quarter of 2014.

EBITDA increased 6.6% to Ps. 408.7 million in the third quarter of 2015, compared to Ps. 383.3 million in the third quarter of 2014. The EBITDA margin decreased 4.1 percentage points, as a percentage of Net Sales, to 27.2% in the third quarter of 2015, from 31.3% in the same period of 2014.

Growth Rates by Country (3Q15 vs 3Q14)

	Local Currency	In Local Currency	In MXN
U.S.A.	**USD**	**97.1%**	**146.7%**
Latam[1]		**21.4%**	**22.7%**
Argentina	ARS	36.1%	52.8%
Brazil, Uruguay and Paraguay	BRL	-9.0%	-26.9%
Colombia	COP	95.1%	57.7%
Ecuador	USD	19.8%	50.1%
Bolivia and Peru	PEN	52.8%	65.8%
Chile and Central America	USD	2.3%	28.3%
Dominican Republic	DOP	-47.2%	-38.4%

[1] Weighted Average

Balance Sheet

As of September 30, 2015, September 30, 2014 and December 31, 2014
(In millions of current Mexican pesos)

	September 30, 2015	September 30, 2014	Var Sep '15 vs Sep '14	% Var Sep '15 vs Sep '14	December 31, 2014	Var Sep '15 vs Dec '14	% Var Sep '15 vs Dec'14
Balance Sheet Information:							
Cash and Equivalents	**2,116.3**	1,345.6	770.7	57.3%	1,182.3	934.0	79.0%
Clients	**3,034.9**	5,750.9	(2,716.0)	-47.2%	4,164.3	(1,129.4)	-27.1%
Inventories	**1,544.4**	1,162.0	382.4	32.9%	1,595.0	(50.6)	-3.2%
Other current Assets	**4,112.8**	1,962.1	2,150.7	109.6%	10,196.6	(6,083.8)	-59.7%
Total Assets	**20,532.4**	18,594.9	1,937.5	10.4%	25,428.3	(4,895.9)	-19.3%
Suppliers	**1,100.6**	1,490.3	(389.7)	-26.1%	1,554.7	(454.1)	-29.2%
Other current Liabilities	**1,605.7**	836.4	769.2	92.0%	5,640.6	(4,034.9)	-71.5%
Current portion of debt	**252.4**	337.5	(85.0)	-25.2%	400.6	(148.1)	-37.0%
Unsecured local bonds	**5,485.6**	3,985.4	1,500.3	37.6%	5,481.7	4.0	0.1%
Long-term Loans with financial institutions	**361.5**	1,752.4	(1,390.9)	-79.4%	1,023.6	(662.1)	-64.7%
Total Liabilities	**9,486.4**	9,116.1	370.3	4.1%	14,925.2	(5,438.8)	-36.4%
Stockholders Equity	**11,046.0**	9,478.8	1,567.2	16.5%	10,503.1	542.9	5.2%
Working Capital (1)	**7,849.7**	7,556.4	293.3	3.9%	9,542.3	(1,692.6)	-17.7%
Working Capital less cash	**5,733.4**	6,210.8	(477.4)	-7.7%	8,360.0	(2,626.6)	-31.4%
Clients days	**97**	167	(70)	-41.6%	130	(33)	-25.0%
Inventories days	**164**	111	53	47.5%	162	2	0.9%
Suppliers days	**117**	142	(25)	-18.0%	158	(41)	-26.2%
Cash Conversion Cycle	**144**	**136**	8	6.2%	134	10	7.5%

(1) Working Capital consists of current assets minus current liabilities.

Cash and Equivalents increased 57.3% (Ps. 770.7 million) to Ps. 2.12 billion as of September 30, 2015, compared to Ps. 1.35 billion as of September 30, 2014. This increase was mainly due to cash generated from our operations during the last twelve months, in addition to the sale of Grupo Marzam, which was offset by banking debt payments and by the repurchase of shares.

Clients amounted to Ps. 3.03 billion as of September 30, 2015, compared to Ps. 5.75 billion as of September 30, 2014. Days of Clients decreased 70 days to 97 days as of September 30, 2015, from 167 days as of September 30, 2014. This decrease, mainly in Mexico and Latam, is the result of the continuous actions implemented to maintain healthy levels of Accounts Receivable with our clients.

Inventories amounted to Ps. 1.54 billion as of September 30, 2015, compared to Ps. 1.16 billion as of September 30, 2014. Days of Inventories increased 53 days to 164 days as of September 30, 2015, compared to 111 days as of September 30, 2014. This increase is related to a higher portion of our consolidated sales coming from the Latam operations, which have higher inventory levels that the Company is working to reduce. In addition, 17 days of this increase are explained by the return of inventories from Grupo Marzam.

Other Current Assets amounted to Ps. 4.11 billion as of September 30, 2015, from Ps. 1.96 billion as of September 30, 2014. This increase is mainly derived from taxes in favor of the Company and advertising paid in advance, as well as payments made in advance to suppliers. In addition, this increase is due to the account receivable related to the sale of Grupo Marzam amounting to Ps. 300 million.

Suppliers amounted to Ps. 1.10 billion as of September 30, 2015, compared to Ps. 1.49 billion as of September 30, 2014. Days of Suppliers decreased 25 days to 117 as of September 30, 2015, from 142 days as of September 30, 2014. This decrease is mainly due to the higher participation of the international operations in our consolidated sales, which have lower Days of Suppliers.

Other Current Liabilities amounted to Ps. 1.61 billion as of September 30, 2015, from Ps. 836.4 million as of September 30, 2014. This increase is mainly derived from taxes and advertising to be paid in our international operations, which increased compared to the same quarter of 2014. In addition, the Company generated an account payable related to the share repurchase program at the end of September, which was paid at the beginning of October.

Financial Debt amounted to Ps. 6.10 billion as of September 30, 2015, compared to 6.08 billion in the same period of 2014. The current portion of long term debt amounted to Ps. 252.4 million, which represents 4.1% of the total debt. With the proceeds of the sale of Grupo Marzam, the Company paid a total of Ps. 950.0 million in debt during the quarter.

As of September 30, 2015 the Net Debt with cost of the Company amounted to Ps. 3.98 billion, which represents a Net Debt to EBITDA ratio of 1.87.

Cash Conversion Cycle reached 144 days at the end of the third quarter of 2015, which represents an increase of eight days compared to the 136 days at the end of the same period of 2014 and an increase of two days compared to the second quarter of 2015. The tendency of the Company's Cash Conversion Cycle has been going down and if we consider the inventory increase from the return of Marzam was a one-time event and exclude it, the Cash Conversion Cycle would be 127.

Cash Conversion Cycle divided by region and account was:

	U.S.A.	**Mexico**	**Latam**
Accounts Receivable	82	122	81
Days of Inventories	129	157	181
Accounts Payable	34	218	31
CCC	**177**	**62**	**231**

New Product Launches and Line Extensions

During the third quarter of 2015, the Company launched 18 line extensions from our **Base Brands** and **Prior Year Launches.** Some of the products recently launched are:

Cicatricure® Night Intervention, a line extension of our brand *Cicatricure*, is a night facial lotion with three powerful peptides that stimulate six essential elements for the skin's reconstitution; it moisturizes and tones the skin of face and neck.

Fermodyl® Bio Effective is a new line of hair care with 3D Alpha, exclusively formulated for hair with specific needs. *Fermodyl Bio Effective* makes hair shiny, giving smoothness in extreme conditions.

X Ray AVA is indicated for the treatment and prevention of osteoarthritis and its symptoms such as pain and inflammation of the affected joints and limitation of joint movement

Other Corporate Events

- Genomma Lab Internacional acquired 51% of the equity interest in Televisa Consumer Products, the Joint Venture it had with Televisa for its operations in the U.S.A., as well as 30% of the equity interest of Lab Brands International LLC, Genomma Lab's subsidiary which holds the brands sold in this country. The Company disbursed Ps. 76.3 million for this operation. As a result, the Company now owns and controls 100% of the operations and brands in the U.S.A.
  Going forward, the subsidiary in the U.S.A. will operate like the rest of the subsidiaries of the Company, including the acquisition of media directly from TV vendors.

- As of September 30, the Company has repurchased a total of 26.2 million shares through its share buyback fund, which is equal to an investment of Ps. 415.9 million. The average price at which the Company has acquired shares throughout 2015 is of Ps. 14.52.

Analyst Coverage

Banco Itaú BBA, S.A.; Barclays Bank PLC; BBVA Bancomer, S.A. Institución de Banca Múltiple; BTG Pactual US Capital LLC; Casa de Bolsa Credit Suisse S.A.; GBM Grupo Bursátil Mexicano, S.A. de C.V. Casa de Bolsa; Grupo Financiero Banorte S.A.B de C.V.; Grupo Financiero Interacciones S.A. de C.V.; HSBC Securities (USA) Inc.; Intercam Casa de Bolsa, S.A. de C.V.; Invex Grupo Financiero S.A. de C.V.; JP Morgan Securities LLC; Santander Investment Securities Inc.; Signum Research; UBS Casa de Bolsa S.A., and Vector Casa de Bolsa.

Company Description

Genomma Lab Internacional, S.A.B. de C.V. is one of the leading pharmaceutical and personal care products companies in Mexico with an increasing international presence. Genomma Lab develops, sells and markets a broad range of premium branded products, many of which are leaders in the categories in which they compete in terms of sales and market share. Genomma Lab relies on the combination of a successful new product development process, a consumer-oriented marketing, a broad retail distribution network and a low-cost, highly flexible operating model.

Genomma Lab's shares are listed on the Mexican Stock Exchange under the ticker symbol "LAB.B" (Bloomberg: labb.mx).

Note on Forward-Looking Statements

Contact:

Investor Relations
Tel: +52 (55) 5081-0000 Ext. 5106
E-mail: inversion@genommalab.com

In New York: Grayling USA, Lucía Domville
Tel: +1 (646) 284-9416
E-mail: genommalab@grayling.com

Income Statement

Genomma Lab Internacional S.A.B. de C.V. and subsidiaries

For the nine and three month periods ended on September 30, 2015 and 2014

(In thousand pesos)

	THIRD QUARTER		VAR	ACCUMULATED		VAR
	2015	2014	%	2015	2014	%
Net Sales	2,624,229	3,359,547	(21.9%)	8,367,463	8,697,669	(3.8%)
Cost of goods sold	826,486	1,045,088	(20.9%)	2,530,387	2,674,308	(5.4%)
Gross Profit	**1,797,743**	**2,314,459**	**(22.3%)**	**5,837,076**	**6,023,361**	**(3.1%)**
Selling, general, marketing and administrative expenses	1,400,828	1,480,135	(5.4%)	4,405,083	4,199,564	4.9%
Other expenses	3,325	908	266.2%	11,817	2,550	363.4%
Other income	(6,244)	16,613	(137.6%)	3,684	18,612	(80.2%)
EBITDA	**387,346**	**850,029**	**(54.4%)**	**1,423,860**	**1,839,859**	**(22.6%)**
Depreciation and amortization	27,823	26,227	6.1%	85,117	69,190	23.0%
Income from Operations	**359,523**	**823,802**	**(56.4%)**	**1,338,743**	**1,770,669**	**(24.4%)**
Interest expense	(103,835)	(91,097)	14.0%	(307,659)	(269,246)	14.3%
Interest income	7,328	2,138	242.8%	17,750	7,965	122.8%
Exchange gain (loss)	(3,376)	(30,653)	(89.0%)	(27,043)	(60,864)	(55.6%)
Comprehensive financing income (cost)	**(99,883)**	**(119,612)**	**(16.5%)**	**(316,952)**	**(322,145)**	**(1.6%)**
Associated company	(1,633)	(1,412)	15.7%	(3,808)	(2,479)	53.6%
Income before income taxes	**258,007**	**702,778**	**(63.3%)**	**1,017,983**	**1,446,045**	**(29.6%)**
Income tax expense	80,669	215,597	(62.6%)	363,328	453,151	(19.8%)
Income from continuing operations	**177,338**	**487,181**	**(63.6%)**	**654,655**	**992,894**	**(34.1%)**
Net income from discontinued operations	11,038	-	100.0%	68,154	-	100.0%
Consolidated net income	**188,376**	**487,181**	**(61.3%)**	**722,809**	**992,894**	**(27.2%)**
Non-controlling interest	5,846	14,631	(60.0%)	43,516	58,943	(26.2%)
Net income of majority stockholders	182,530	472,550	(61.4%)	679,293	933,951	(27.3%)

Balance Sheet

Genomma Lab Internacional S.A.B. de C.V. and subsidiaries

As of September 30, 2015 and 2014 and December 31, 2014

(In thousand pesos)

ASSETS	SEPTEMBER 2015	SEPTEMBER 2014	VARIATION Amount	VARIATION %	DECEMBER 2014	VARIATION Amount	VARIATION %
Current assets							
Cash and equivalents	2,098,999	1,336,550	762,449	57%	1,164,454	934,545	80%
Restricted fund	17,271	9,037	8,234	91%	17,842	(571)	(3%)
Clients - Net	3,034,867	5,750,877	(2,716,010)	(47%)	4,164,311	(1,129,444)	(27%)
Other accounts receivable	2,143,486	766,350	1,377,136	180%	1,307,094	836,392	64%
Inventory - Net	1,544,449	1,161,999	382,450	33%	1,595,012	(50,563)	(3%)
Prepaid expenses	1,969,325	1,195,742	773,583	65%	1,098,990	870,335	79%
Assets classified as held for sale	-	-	-	-	7,790,506	(7,790,506)	(100%)
Total current assets	**10,808,397**	**10,220,555**	**587,842**	**6%**	**17,138,209**	**(6,329,812)**	**(37%)**
Non-current assets							
Trademarks	7,057,934	6,438,627	619,307	10%	6,928,043	129,891	2%
Investment in shares	1,367,140	615,733	751,407	122%	18,360	1,348,780	7346%
Buildings, properties and equipment – Net	407,291	441,888	(34,597)	(8%)	457,659	(50,368)	(11%)
Deferred income tax	76,989	75,539	1,450	2%	79,233	(2,244)	(3%)
Other assets - Net	814,630	802,548	12,082	2%	806,811	7,819	1%
Total non-current assets	**9,723,984**	**8,374,335**	**1,349,649**	**16%**	**8,290,106**	**1,433,878**	**17%**
Total assets	**20,532,381**	**18,594,890**	**1,937,491**	**10%**	**25,428,315**	**(4,895,934)**	**(19%)**
LIABILITIES AND STOCKHOLDERS' EQUITY							
Current Liabilities							
Current portion of long-term debt	252,432	337,455	(85,023)	(25%)	400,579	(148,147)	(37%)
Suppliers	1,100,611	1,490,297	(389,686)	(26%)	1,554,690	(454,079)	(29%)
Due to related parties	12,495	-	12,495	100%	-	12,495	100%
Other current liabilities	1,323,388	705,646	617,742	88%	1,012,915	310,473	31%
Income tax payable	252,326	122,968	129,358	105%	126,477	125,849	100%
Statutory employee profit sharing	17,462	7,832	9,630	123%	13,827	3,635	26%
Debts classified as held for sale	-	-	-	-	4,487,400	(4,487,400)	(100%)
Total current liabilities	**2,958,714**	**2,664,198**	**294,516**	**11%**	**7,595,888**	**(4,637,174)**	**(61%)**
Non-current liabilities							
Long-term debt securities	5,485,639	3,985,353	1,500,286	38%	5,481,665	3,974	0%
Long-term loans with financial institutions	361,504	1,752,447	(1,390,943)	(79%)	1,023,613	(662,109)	(65%)
Other long term liabilities	53,984	63,203	(9,219)	(15%)	64,820	(10,836)	(17%)
Deferred income tax	623,682	648,431	(24,749)	(4%)	756,924	(133,242)	(18%)
Employee retirement obligations	2,879	2,474	405	16%	2,298	581	25%
Total liabilities	**9,486,402**	**9,116,106**	**370,296**	**4%**	**14,925,208**	**(5,438,806)**	**(36%)**
Stockholders' equity							
Capital stock	1,914,306	1,914,306	-	-	1,914,306	-	-
Retained earnings	8,263,564	6,428,565	1,834,999	29%	6,819,006	1,444,558	21%
Net income	679,293	933,951	(254,658)	(27%)	1,444,558	(765,265)	(53%)
Cumulative translation effects of foreing subsidiaries	372,433	57,649	314,784	546%	149,561	222,872	149%
Share buy back fund	(468,688)	(84,142)	(384,546)	457%	(74,394)	(394,294)	530%
Net premium in placement of repurchased shares	39,749	39,749	-	-	39,749	-	-
Minority interest	245,322	188,706	56,616	30%	210,321	35,001	17%
Total stockholders' equity	**11,045,979**	**9,478,784**	**1,567,195**	**17%**	**10,503,107**	**542,872**	**5%**
Total equity and liabilities	**20,532,381**	**18,594,890**	**1,937,491**	**10%**	**25,428,315**	**(4,895,934)**	**(19%)**

Cash Flow

Genomma Lab Internacional S.A.B. de C.V. and subsidiaries

For the nine and three month periods ended on September 30, 2015

(In thousand pesos)

	SEPTEMBER 2015	
	3rd QUARTER	ACCUMULATED
Cash and cash equivalents at the beginning of the period	**1,731,723**	**1,182,296**
Consolidated Net Income	**188,375**	**722,808**
Charges to results with no cash flow:		
Depreciation and amortization	27,822	85,117
Income tax	80,668	363,327
Accrued interest and others	81,546	213,583
	378,411	**1,384,835**
Changes in Working Capital:		
Clients - Net	226,168	1,129,442
Inventories	(71,818)	50,565
Suppliers	62,682	(454,515)
Other current assets	(803,723)	(1,416,678)
Paid income tax	(71,232)	(332,326)
Other current liabilities	81,070	157,962
Variation in assets available for sale	599,206	671,260
	22,353	**(194,290)**
Net cash generated (used) in operating activities	**400,764**	**1,190,545**
Investing activities:		
Investment in fixed assets	(14,164)	(30,784)
Sales of equipment	1,040	19,349
Brand acquisitions and others	(12,802)	(14,607)
Disposals of assets available for sale	1,050,000	1,050,000
Other non-current assets	(6,306)	(16,910)
Net cash generated (used) in investing activities	**1,017,768**	**1,007,048**
Financing activities:		
Payments of borrowings from financial institutions	(1,154,212)	(1,516,021)
Loans financial institutions	160,333	715,878
Interest paid	(92,141)	(264,427)
Stock repurchase	(15,750)	(252,409)
Minority interest	20,080	(8,514)
Net cash used in financing activities	**(1,081,690)**	**(1,325,493)**
Net increase in cash and cash equivalents before foreign exchange adjustments coming from international operations and inflationary affects cash	**336,842**	**872,100**
Foreign exchange and inflationary effects from international operations	47,705	61,874
Accumulated cash flow at the end of the period	**2,116,270**	**2,116,270**
Less - restricted fund	17,271	17,271
Cash and cash equivalents at the end of the period	**2,098,999**	**2,098,999**